Search Result

Results for "

thrombopoietin receptor agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Thrombopoietin Receptor (18) Apoptosis (5) Bacterial (5) Cyclin G-associated Kinase (GAK) (2) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (9) Cardiovascular Disease (10) Infection (5) Inflammation/Immunology (8)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Isotope-Labeled Compounds

Targets Recommended: Thrombopoietin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19883

Lusutrombopag 2 Publications Verification S-888711	Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease.

HY-19883S

Lusutrombopag-d13 S-888711-d₁₃	Isotope-Labeled Compounds Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag-d₁₃ is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.

HY-122620

Rafutrombopag (tautomerism) Hetrombopag (tautomerism); SHR-8735 (tautomerism)	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Rafutrombopag (tautomerism) is a potent **thrombopoietin receptor** agonist. Rafutrombopag (tautomerism) is efficacious and well tolerated with a manageable safety profile. Rafutrombopag (tautomerism) has the potential for the research of immune thrombocytopenia .

HY-112486

TA-316 Megakaryocytes/platelets inducing agent	Cyclin G-associated Kinase (GAK)	Cardiovascular Disease
TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and **thrombopoietin (TPO) receptor** agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells .

HY-125101A

Rafutrombopag diolamine	Thrombopoietin Receptor	Cardiovascular Disease
Rafutrombopag diolamine is the derivative of Rafutrombopag. Rafutrombopag is a thrombopoietin receptor agonist .

HY-14756

Totrombopag	Thrombopoietin Receptor	Others
Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .

HY-135041

Totrombopag choline SB-559448 choline	Thrombopoietin Receptor	Others
Totrombopag (SB-559448) choline is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag choline initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag choline can be used to study platelet production and megakaryocyte biology .

HY-153239

Eltrombopag methyl ester	Thrombopoietin Receptor	Inflammation/Immunology
Eltrombopag methyl ester is a derivative of Eltrombopag, which is a **thrombopoietin (Tpo) receptor** agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .

HY-19883R

Lusutrombopag (Standard)	Thrombopoietin Receptor	Inflammation/Immunology
Lusutrombopag (Standard) is the analytical standard of Lusutrombopag. This product is intended for research and analytical applications. Lusutrombopag is an orally bioavailable **thrombopoietin (TPO) receptor** agonist, used for treatment of chronic liver disease.

HY-112486G

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Cyclin G-associated Kinase (GAK)	Cardiovascular Disease
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

HY-13463B

Avatrombopag hydrochloride 3 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease Cancer
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463

Avatrombopag 3 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463A

Avatrombopag maleate 3 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor	Inflammation/Immunology
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC₅₀=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15306

Eltrombopag Maximum Cited Publications 15 Publications Verification SB-497115	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306A

Eltrombopag Olamine Maximum Cited Publications 15 Publications Verification Eltrombopag diethanolamine salt; SB-497115GR	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306S

Eltrombopag-13C4 1 Publications Verification SB-497115-¹³C₄	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-13463R

Avatrombopag (Standard)	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide **thrombopoietin (TPO) receptor** agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d₈ hydrochloride; E5501-d₈ hydrochloride; YM477-d₈ hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

HY-15306R

Eltrombopag (Standard)	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .

HY-15306AR

Eltrombopag (Olamine) (Standard)	Thrombopoietin Receptor Bacterial Apoptosis	Infection Cardiovascular Disease Cancer
Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active **thrombopoietin receptor** nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Fluorescent Dye
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

Cat. No.	Product Name	Type

HY-112486G

TA-316 (GMP) Megakaryocytes/platelets inducing agent (GMP)	Biochemical Assay Reagents
TA-316 (GMP) is TA-316 (HY-112486) produced by using GMP guidelines. GMP grade small molecules can be used as auxiliary agents in cell therapy. TA-316 is a c-MPL agonist and a thrombopoietin (TPO) receptor agonist .

Cat. No.	Product Name	Chemical Structure

HY-19883S

Lusutrombopag-d13
Lusutrombopag-d₁₃ is deuterium labeled Lusutrombopag. Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.

HY-15306S

Eltrombopag-13C4 1 Publications Verification
Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

Eltrombopag-13C4

1 Publications Verification

Eltrombopag- ¹³C₄ (SB-497115- ¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .}

HY-13463BS

Avatrombopag-d8 hydrochloride
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.